Title |
Nanobodies as novel agents for disease diagnosis and therapy
|
---|---|
Published in |
International Journal of Nanomedicine, November 2013
|
DOI | 10.2147/ijn.s39428 |
Pubmed ID | |
Authors |
Christina G Siontorou |
Abstract |
The discovery of naturally occurring, heavy-chain only antibodies in Camelidae, and their further development into small recombinant nanobodies, presents attractive alternatives in drug delivery and imaging. Easily expressed in microorganisms and amenable to engineering, nanobody derivatives are soluble, stable, versatile, and have unique refolding capacities, reduced aggregation tendencies, and high-target binding capabilities. This review outlines the current state of the art in nanobodies, focusing on their structural features and properties, production, technology, and the potential for modulating immune functions and for targeting tumors, toxins, and microbes. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 2 | <1% |
United States | 2 | <1% |
France | 1 | <1% |
Belgium | 1 | <1% |
Mexico | 1 | <1% |
Unknown | 273 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 53 | 19% |
Student > Ph. D. Student | 47 | 17% |
Researcher | 45 | 16% |
Student > Bachelor | 27 | 10% |
Student > Doctoral Student | 19 | 7% |
Other | 32 | 11% |
Unknown | 57 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 69 | 25% |
Agricultural and Biological Sciences | 61 | 22% |
Medicine and Dentistry | 17 | 6% |
Immunology and Microbiology | 13 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 11 | 4% |
Other | 47 | 17% |
Unknown | 62 | 22% |